NCT05276076尚未招募1 期
A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 12
- 主要终点
- Maximum Tolerated Dose (MTD) of VM-001 [ Time Frame: 1 week ]
研究概览
简要总结
The present study is multi center, phase I/IIa clinical trial to evaluate the safety and pharmacodynamics of investigational Product (VM-001) in patients with graft-versus-host disease(GvHD). A total of 12 subjects (Part 1 SAD[3 cohort(2 subjects/cohort)], Part 2 MAD[2 cohort(3subjects/cohort)]) are recruited.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women ≥19 years of age
- •Acute GvHD or chronic GvHD after hematopoietic stem cell transplant
- •Subjects who no longer have available standard treatment.
- •ANC≥1,000cells./mm^3
- •AST, ALT, total bilirubin less than 3 times the upper limit of normal
- •serum creatinine less than 1.5 times the upper limit of normal
排除标准
- •Received an anti-thymocyte globulin(ATG) within 14 days before enrollment
- •FCV or FEV less than 70%
- •Any uncontrolled infection or active infection requiring ongoing systemic treatment
- •Received an investigational agent within 6 months before enrollment.
- •Evidence of bleeding diathesis or coagulopathy.
- •Active hepatitis C virus (HCV) or hepatitis B virus (HBV)
- •Breastfeeding or pregnant.
结局指标
主要结局
Maximum Tolerated Dose (MTD) of VM-001 [ Time Frame: 1 week ]
时间窗: 7 day cycle
First 7-day treatment dose limiting toxicities (DLT) graded according to CTCAE in the MTD-determining population in Phase 1 based on the number of participants with adverse effects as measure of tolerability at various dose levels
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid TumorsNeoplasmsNCT01143753Hoffmann-La Roche45
终止
1 期
A Study to Evaluate THB001 in Adult Patients With Chronic Cold UrticariaChronic Cold UrticariaNCT05510843Third Harmonic Bio, Inc.5
已完成
1 期
A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid TumorsSolid TumorsNCT01603979AVEO Pharmaceuticals, Inc.24
进行中（未招募）
1 期
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid TumorsAdvanced Solid Tumors CancerNCT02988960AbbVie163
招募中
1 期
Safety Evaluation Study for Patients With Aggressive NK-cell LeukemiaAggressive NK Cell LeukemiaNCT05863234Hiroshima University Hospital7